Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Samsell B, Moore M, Bertasi G, Spinato S, Bernardello F, Rebaudi A, Sfasciotti GL, Powers R. Are bone allografts safe and effective for today's dental practitioner? Dentistry. 2014 Nov 3;4(9):1000260. doi: 10.4172/2161-1122.1000260
Bernfort L, Brodtkorb T. QALY som effektmått inom vården : möjligheter och begränsningar. Linköping: linköping University Electronic Press. Cmt- Rapport. 2012.
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Brodtkorb T. National system for assessment, prioritization and introduction of non-pharmaceutical health technologies, a pilot study. Cmt- Rapport. 2010.